.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective requires addition of individuals with MASLD and measurement of liver results in cardio-- kidney-- metabolic trials, when records recommend mechanistically tenable advantages and clinical safety and security-- and also lays out factors to consider for trial design as well as regulatory commendation.